small molecule

ZEMBRACE SYMTOUCH

SUMATRIPTAN SUCCINATE

Loss of exclusivityJanuary 2036latest FDA-listed patent expiry
CompanyTONIX MEDICINES INC

Drug detail

Brand nameZEMBRACE SYMTOUCH
Active ingredientSUMATRIPTAN SUCCINATE
StrengthEQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJanuary 2016
Marketing statusRX

Listed patents

PatentExpiresType
10537554January 2036use U-72
11364224January 2036use U-72
12097183January 2036product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ZEMBRACE SYMTOUCH patent cliff — loss of exclusivity January 2036 | CliffBio